NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 155 filers reported holding NEKTAR THERAPEUTICS in Q1 2015. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $394,000 | -55.0% | 8,068 | -2.0% | 0.28% | -58.2% |
| Q1 2018 | $875,000 | -16.5% | 8,230 | -53.1% | 0.67% | -17.7% |
| Q4 2017 | $1,048,000 | +5.6% | 17,542 | -57.5% | 0.82% | -6.8% |
| Q3 2017 | $992,000 | +22.5% | 41,316 | -0.3% | 0.88% | +22.8% |
| Q2 2017 | $810,000 | -18.0% | 41,420 | -1.6% | 0.71% | -7.0% |
| Q1 2017 | $988,000 | +91.1% | 42,109 | -0.0% | 0.77% | +92.5% |
| Q4 2016 | $517,000 | -31.3% | 42,124 | -3.9% | 0.40% | -35.2% |
| Q3 2016 | $753,000 | +13.6% | 43,851 | -6.0% | 0.62% | +3.5% |
| Q2 2016 | $663,000 | -70.9% | 46,626 | -71.8% | 0.60% | -69.1% |
| Q1 2016 | $2,277,000 | -25.2% | 165,584 | -8.3% | 1.92% | -13.0% |
| Q4 2015 | $3,043,000 | +47.5% | 180,601 | -4.0% | 2.21% | +50.6% |
| Q3 2015 | $2,063,000 | +184.2% | 188,220 | +224.2% | 1.47% | +220.0% |
| Q2 2015 | $726,000 | +53.8% | 58,053 | +35.2% | 0.46% | +67.5% |
| Q1 2015 | $472,000 | – | 42,938 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |